EWTX logo

Edgewise Therapeutics (EWTX) Cash From Operations

Annual CFO

-$109.03 M
-$17.08 M-18.58%

December 31, 2024


Summary


Performance

EWTX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherEWTXcash flowmetrics:

Quarterly CFO

-$26.96 M
+$417.00 K+1.52%

December 31, 2024


Summary


Performance

EWTX Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherEWTXcash flowmetrics:

TTM CFO

-$109.03 M
-$127.00 K-0.12%

December 31, 2024


Summary


Performance

EWTX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherEWTXcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

EWTX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-18.6%+1.5%-0.1%
3 y3 years-225.4%-22.2%-41.6%
5 y5 years-1088.8%-22.2%-41.6%

EWTX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-225.4%at low-186.2%+5.7%-225.4%at low
5 y5-year-1088.8%at low-884.2%+5.7%-3880.6%at low
alltimeall time-1088.8%at low-884.2%+5.7%-3880.6%at low

Edgewise Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2024
-$109.03 M(+18.6%)
-$26.96 M(-1.5%)
-$109.03 M(+0.1%)
Sep 2024
-
-$27.37 M(+4.9%)
-$108.90 M(+5.1%)
Jun 2024
-
-$26.10 M(-8.7%)
-$103.58 M(+6.0%)
Mar 2024
-
-$28.60 M(+6.6%)
-$97.72 M(+6.3%)
Dec 2023
-$91.95 M(+74.7%)
-$26.83 M(+21.6%)
-$91.95 M(+19.5%)
Sep 2023
-
-$22.06 M(+9.0%)
-$76.97 M(+15.1%)
Jun 2023
-
-$20.23 M(-11.4%)
-$66.88 M(+6.3%)
Mar 2023
-
-$22.83 M(+92.5%)
-$62.89 M(+19.5%)
Dec 2022
-$52.63 M
-$11.86 M(-0.9%)
-$52.63 M(+4.9%)
Sep 2022
-
-$11.96 M(-26.4%)
-$50.20 M(+8.0%)
DateAnnualQuarterlyTTM
Jun 2022
-
-$16.25 M(+29.2%)
-$46.50 M(+16.2%)
Mar 2022
-
-$12.57 M(+33.5%)
-$40.02 M(+19.4%)
Dec 2021
-$33.51 M(+129.0%)
-$9.42 M(+14.0%)
-$33.51 M(+16.6%)
Sep 2021
-
-$8.26 M(-15.4%)
-$28.73 M(+21.0%)
Jun 2021
-
-$9.77 M(+61.3%)
-$23.74 M(+32.2%)
Mar 2021
-
-$6.06 M(+30.6%)
-$17.95 M(+22.7%)
Dec 2020
-$14.63 M(+59.6%)
-$4.64 M(+41.7%)
-$14.63 M(+46.4%)
Sep 2020
-
-$3.27 M(-17.9%)
-$10.00 M(+48.7%)
Jun 2020
-
-$3.98 M(+45.5%)
-$6.72 M(+145.5%)
Mar 2020
-
-$2.74 M
-$2.74 M
Dec 2019
-$9.17 M
-
-

FAQ

  • What is Edgewise Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Edgewise Therapeutics?
  • What is Edgewise Therapeutics annual CFO year-on-year change?
  • What is Edgewise Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Edgewise Therapeutics?
  • What is Edgewise Therapeutics quarterly CFO year-on-year change?
  • What is Edgewise Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Edgewise Therapeutics?
  • What is Edgewise Therapeutics TTM CFO year-on-year change?

What is Edgewise Therapeutics annual cash flow from operations?

The current annual CFO of EWTX is -$109.03 M

What is the all time high annual CFO for Edgewise Therapeutics?

Edgewise Therapeutics all-time high annual cash flow from operations is -$9.17 M

What is Edgewise Therapeutics annual CFO year-on-year change?

Over the past year, EWTX annual cash flow from operations has changed by -$17.08 M (-18.58%)

What is Edgewise Therapeutics quarterly cash flow from operations?

The current quarterly CFO of EWTX is -$26.96 M

What is the all time high quarterly CFO for Edgewise Therapeutics?

Edgewise Therapeutics all-time high quarterly cash flow from operations is -$2.74 M

What is Edgewise Therapeutics quarterly CFO year-on-year change?

Over the past year, EWTX quarterly cash flow from operations has changed by +$417.00 K (+1.52%)

What is Edgewise Therapeutics TTM cash flow from operations?

The current TTM CFO of EWTX is -$109.03 M

What is the all time high TTM CFO for Edgewise Therapeutics?

Edgewise Therapeutics all-time high TTM cash flow from operations is -$2.74 M

What is Edgewise Therapeutics TTM CFO year-on-year change?

Over the past year, EWTX TTM cash flow from operations has changed by -$127.00 K (-0.12%)